{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"283"},{"groupId":"OG001","value":"147"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"299"},{"groupId":"OG001","value":"153"}],"units":"Participants"}],"description":"An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study therapy and irrespective of causality to study therapy.","groups":[{"description":"Participants received 200 mg pembrolizumab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus BSC.","id":"OG000","title":"Pembrolizumab + BSC"},{"description":"Participants received placebo by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus BSC.","id":"OG001","title":"Placebo + BSC"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Randomized participants who received at least 1 dose of study intervention.","reportingStatus":"POSTED","timeFrame":"Up to approximately 30 months.","title":"Number of Participants Who Experienced At Least One Adverse Event (AE)","type":"SECONDARY","unitOfMeasure":"Participants"}